Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 14/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879519 | 0.80 | TAS2R8 (0.43) | TAS2R8 | |
| SCHEMBL13879480 | 0.71 | CDC25B (0.42) | — | |
| SCHEMBL13879442 | 0.71 | ALOX15 (0.43) | — | |
| SCHEMBL13879377 | 0.70 | PKM (0.41) | — | |
| SCHEMBL13879405 | 0.66 | TAS2R8 (0.54) | TAS2R8 | |
| SCHEMBL14366420 | 0.65 | CYP1A2 (0.37) | POLB | |
| SCHEMBL796887 | 0.65 | CYP1A2 (0.37) | POLB | |
| SCHEMBL13879513 | 0.64 | NPSR1 (0.56) | POLB | |
| SCHEMBL2824162 | 0.60 | ALDH1A1 (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CPOLB | |
| SCHEMBL12555510 | 0.60 | TSHR (0.41) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TAS2R8 4662/4885CACNA1F 4713/4885CACNA1D 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.